{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:55:32Z","timestamp":1792569332521,"version":"4.5.0"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1003037","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T13:23:33Z","timestamp":1582637013000},"page":"e1003037","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":51,"title":["Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-5852","authenticated-orcid":true,"given":"Lucas E.","family":"Hermans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6792-4748","authenticated-orcid":true,"given":"Sergio","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Nijhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6119-4003","authenticated-orcid":true,"given":"Hugo A.","family":"Tempelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0962-9254","authenticated-orcid":true,"given":"Douglas D.","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8410-3247","authenticated-orcid":true,"given":"Michelle","family":"Moorhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederick E.","family":"Grobbee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4157-732X","authenticated-orcid":true,"given":"Willem D. F.","family":"Venter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-8891","authenticated-orcid":true,"given":"Annemarie M. J.","family":"Wensing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"pmed.1003037.ref001","article-title":"90-90-90 An ambitious treatment target to help end the AIDS epidemic","author":"UNAIDS","year":"2014"},{"key":"pmed.1003037.ref002","article-title":"Ending AIDS: Progress towards the 90-90-90 targets","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)","year":"2017"},{"key":"pmed.1003037.ref003","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"PE Sax","year":"2017","journal-title":"Lancet"},{"issue":"18","key":"pmed.1003037.ref004","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1097\/QAD.0000000000000878","article-title":"The HIV care cascade in Switzerland: Reaching the UNAIDS\/WHO targets for patients diagnosed with HIV","volume":"29","author":"P Kohler","year":"2015","journal-title":"AIDS"},{"issue":"4","key":"pmed.1003037.ref005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/hiv.12431","article-title":"Sweden, the first country to achieve the Joint United Nations Programme on HIV\/AIDS (UNAIDS)\/World Health Organization (WHO) 90-90-90 continuum of HIV care targets","volume":"18","author":"M Gissl\u00e9n","year":"2017","journal-title":"HIV Med"},{"key":"pmed.1003037.ref006","article-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection.","author":"World Health Organization","year":"2016"},{"issue":"7","key":"pmed.1003037.ref007","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1128\/AAC.00076-14","article-title":"Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients","volume":"58","author":"P Ryscavage","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pmed.1003037.ref008","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S1473-3099(17)30681-3","article-title":"Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: A multicentre cohort study","volume":"18","author":"LE Hermans","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"pmed.1003037.ref009","unstructured":"European AIDS Clinical Society. EACS Guidelines Version 9.0. 2018 [cited 2020 Feb 6]. Available from: www.eacsociety.org\/files\/2018_guidelines-9.1-english.pdf"},{"key":"pmed.1003037.ref010","unstructured":"Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2018 [cited 2020 Feb 6]. Available from: https:\/\/aidsinfo.nih.gov\/guidelines"},{"issue":"2","key":"pmed.1003037.ref011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3851\/IMP2010","article-title":"Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients","volume":"17","author":"RE Barth","year":"2012","journal-title":"Antivir Ther"},{"issue":"6629","key":"pmed.1003037.ref012","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/387183a0","article-title":"Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection","volume":"387","author":"TW Chun","year":"1997","journal-title":"Nature"},{"issue":"10","key":"pmed.1003037.ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement","volume":"12","author":"EI Benchimol","year":"2015","journal-title":"PLoS Med"},{"issue":"12","key":"pmed.1003037.ref014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1002468","article-title":"Estimating the impact of antiretroviral treatment on adult mortality trends in South Africa: A mathematical modelling study","volume":"14","author":"LF Johnson","year":"2017","journal-title":"PLoS Med"},{"issue":"7","key":"pmed.1003037.ref015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0131353","article-title":"Trends in AIDS deaths, new infections and ART coverage in the top 30 countries with the highest AIDS mortality burden; 1990\u20132013","volume":"10","author":"R Granich","year":"2015","journal-title":"PLoS ONE"},{"issue":"8","key":"pmed.1003037.ref016","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/QAD.0000000000000203","article-title":"HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure","volume":"28","author":"LC Swenson","year":"2014","journal-title":"AIDS"},{"issue":"28","key":"pmed.1003037.ref017","doi-asserted-by":"crossref","first-page":"e3985","DOI":"10.1097\/MD.0000000000003985","article-title":"Should viral load thresholds be lowered?","volume":"95","author":"ND Labhardt","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"pmed.1003037.ref018","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment\u2014Guidance for Industry. 2015 [cited 2020 Feb 6]. Available from: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm355128.pdf"},{"issue":"1","key":"pmed.1003037.ref019","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/QAI.0000000000000553","article-title":"Retention of Adult Patients on Antiretroviral Therapy in Low- and Middle-Income Countries: Systematic Review and Meta- analysis 2008\u20132013","volume":"69","author":"MP Fox","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"pmed.1003037.ref020","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/cid\/ciy347","article-title":"Outcomes of Patients Lost to Follow-up in African Antiretroviral Therapy Programs: Individual Patient Data Meta-analysis","volume":"67","author":"F Chammartin","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"326","key":"pmed.1003037.ref021","first-page":"1","article-title":"Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015","volume":"17","author":"L Bulage","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"93","key":"pmed.1003037.ref022","first-page":"1","article-title":"Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study","volume":"8","author":"KL Fielding","year":"2008","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pmed.1003037.ref023","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/QAI.0b013e3181c22d19","article-title":"Mortality Associated With Discordant Responses to Antiretroviral Therapy in Resource-Constrained Settings","volume":"53","author":"The Antiretroviral Therapy in Low Income Countries (ART-LINC) Collaboration of the International Epidemiologic Databases to Evaluate AIDS","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"pmed.1003037.ref024","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-3156.2009.02445.x","article-title":"Mortality after failure of antiretroviral therapy in sub-Saharan Africa","volume":"15","author":"O Keiser","year":"2010","journal-title":"Trop Med Int Heal"},{"issue":"12","key":"pmed.1003037.ref025","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1086\/648444","article-title":"Viremia, resuppression, and the time to resistance in HIV subtype C during first line antiretroviral therapy in South Africa","volume":"49","author":"CJ Hoffmann","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pmed.1003037.ref026","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/QAI.0000000000001479","article-title":"Brief Report: Appraising Viral Load Thresholds and Adherence Support Recommendations in the World Health Organization Guidelines for Detection and Management of Virologic Failure","volume":"76","author":"SM McCluskey","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"pmed.1003037.ref027","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3851\/IMP1819","article-title":"Early outcomes and the virologic impact of delayed treatment switching on second-line therapy in an antiretroviral roll-out program in South Africa","volume":"16","author":"JH Levison","year":"2011","journal-title":"Antivir Ther"},{"issue":"8","key":"pmed.1003037.ref028","doi-asserted-by":"crossref","first-page":"e0220337","DOI":"10.1371\/journal.pone.0220337","article-title":"The viral load monitoring cascade in a resource-limited setting: A prospective multicentre cohort study after introduction of routine viral load monitoring in rural Lesotho","volume":"14","author":"TR Glass","year":"2019","journal-title":"PLoS ONE"},{"issue":"4","key":"pmed.1003037.ref029","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/QAD.0b013e328333bfb7","article-title":"Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa","volume":"24","author":"A Boulle","year":"2010","journal-title":"AIDS"},{"issue":"10144","key":"pmed.1003037.ref030","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(18)31070-5","article-title":"Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society\u2014Lancet Commission","volume":"392","author":"L-G Bekker","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"pmed.1003037.ref031","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/cid\/cit627","article-title":"Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia","volume":"58","author":"AF Aghokeng","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pmed.1003037.ref032","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/cid\/ciy228","article-title":"Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir","volume":"67","author":"JA Fulcher","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pmed.1003037.ref033","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/infdis\/jiy176","article-title":"HIV-1 resistance dynamics in patients failing dolutegravir maintenance monotherapy","volume":"218","author":"IEA Wijting","year":"2018","journal-title":"J Infect Dis"},{"issue":"9","key":"pmed.1003037.ref034","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/cid\/civ556","article-title":"Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis","volume":"61","author":"TS Boender","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pmed.1003037.ref035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.19.1.20798","article-title":"Treatment failure and drug resistance in hiv-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya","volume":"19","author":"K Brooks","year":"2016","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"pmed.1003037.ref036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.19.1.20773","article-title":"First-line antiretroviral therapy durability in a 10-year cohort of na\u00efve adults started on treatment in Uganda","volume":"19","author":"B Castelnuovo","year":"2016","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"pmed.1003037.ref037","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/jac\/dkx095","article-title":"Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression","volume":"72","author":"AJ Ntamatungiro","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"pmed.1003037.ref038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0186726","article-title":"Outcomes of an HIV cohort after a decade of comprehensive care at Newlands Clinic in Harare, Zimbabwe: TENART cohort","volume":"12","author":"T Shamu","year":"2017","journal-title":"PLoS ONE"},{"key":"pmed.1003037.ref039","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijid.2018.10.019","article-title":"Patterns of detectable viraemia among children and adults with HIV infection taking antiretroviral therapy in Zimbabwe","volume":"78","author":"E Sovershaeva","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"1","key":"pmed.1003037.ref040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-018-3639-y","article-title":"Viral load detection and management on first line ART in rural Rwanda","volume":"19","author":"JDD Ndagijimana Ntwali","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pmed.1003037.ref041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.20.1.21803","article-title":"When patients fail UNAIDS\u2019 last 90\u2014The \u201cfailure cascade\u201d beyond 90-90-90 in rural Lesotho, Southern Africa: A prospective cohort study: A","volume":"20","author":"ND Labhardt","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"pmed.1003037.ref042","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eclinm.2018.06.005","article-title":"Nationwide Estimates of Viral Load Suppression and Acquired HIV Drug Resistance in Cameroon","volume":"1","author":"GF Tchouwa","year":"2018","journal-title":"EClinicalMedicine"},{"issue":"10","key":"pmed.1003037.ref043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jia2.25194","article-title":"Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second-line switches in Swaziland","volume":"21","author":"D Etoori","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"pmed.1003037.ref044","doi-asserted-by":"crossref","first-page":"ciz214","DOI":"10.1093\/cid\/ciz214","article-title":"Better Virological Outcomes Among People Living With Human Immunodeficiency Virus (HIV) Initiating Early Antiretroviral Treatment (CD4 Counts \u2265500 Cells\/\u03bcL) in the HIV Prevention Trials Network 071 (PopART) Trial in South Africa","author":"G Fatti","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pmed.1003037.ref045","first-page":"1","article-title":"Botswana\u2019s Progress Toward Achieving the 2020 UNAIDS 90\u201390\u201390 Antiretroviral Treatment and Virologic Suppression Goals: Results of a Population-Based Survey","volume":"3","author":"Tendani Gaolathe","year":"2016","journal-title":"Lancet HIV"},{"issue":"2","key":"pmed.1003037.ref046","doi-asserted-by":"crossref","first-page":"e0116144","DOI":"10.1371\/journal.pone.0116144","article-title":"Factors Associated with Virological Failure and Suppression after Enhanced Adherence Counselling, in Children, Adolescents and Adults on Antiretroviral Therapy for HIV in Swaziland","volume":"10","author":"K Jobanputra","year":"2015","journal-title":"PLoS ONE"},{"issue":"1","key":"pmed.1003037.ref047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-016-1940-2","article-title":"Imputing HIV treatment start dates from routine laboratory data in South Africa: A validation study","volume":"17","author":"M Maskew","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"pmed.1003037.ref048","doi-asserted-by":"crossref","first-page":"e1002589","DOI":"10.1371\/journal.pmed.1002589","article-title":"Estimating retention in HIV care accounting for patient transfers: A national laboratory cohort study in South Africa","volume":"15","author":"MP Fox","year":"2018","journal-title":"PLoS Med"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T13:23:52Z","timestamp":1582637032000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003037"}},"subtitle":[],"editor":[{"given":"Marie-Louise","family":"Newell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003037","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,25]]}}}